Q2 2017 13F Holders as of 6/30/2017
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
115M
-
Number of holders
-
102
-
Total 13F shares, excl. options
-
39.7M
-
Shares change
-
+2.92M
-
Total reported value, excl. options
-
$569M
-
Value change
-
+$24.4M
-
Put/Call ratio
-
0.38
-
Number of buys
-
69
-
Number of sells
-
-44
-
Price
-
$14.35
Significant Holders of Coherus Oncology, Inc. - Common Stock (CHRS) as of Q2 2017
142 filings reported holding CHRS - Coherus Oncology, Inc. - Common Stock as of Q2 2017.
Coherus Oncology, Inc. - Common Stock (CHRS) has 102 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 39.7M shares
of 115M outstanding shares and own 34.36% of the company stock.
Largest 10 shareholders include FMR LLC (7.69M shares), WELLINGTON MANAGEMENT GROUP LLP (4.9M shares), Kohlberg Kravis Roberts & Co. L.P. (3.06M shares), BlackRock Inc. (2.95M shares), VANGUARD GROUP INC (2.26M shares), Partner Fund Management, L.P. (1.8M shares), STATE STREET CORP (1.42M shares), JPMORGAN CHASE & CO (1.39M shares), UBS ASSET MANAGEMENT AMERICAS INC (1.39M shares), and ORBIMED ADVISORS LLC (1.08M shares).
This table shows the top 102 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.